We have developed a new 3D brain organoid in vitro technology, which, combined with our own analytical algorithms, creates a state-of-the-art pre-clinical phase drug development platform. The 3D models built on our platform can more accurately predict the efficacy of drugs on humans than conventional systems. With this technology, we have developed several promising PD drug candidates. Our business model is to out-license these molecules.